As of 2025-07-04, the EV/EBITDA ratio of Recro Pharma Inc (REPH) is
18.93.
EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. REPH's latest enterprise value
is 170.53 mil USD. REPH's TTM EBITDA according to its financial statements is
9.01 mil USD. Dividing these 2
quantities gives us the above REPH EV/EBITDA ratio.
|
Range |
Selected |
| Trailing P/E multiples |
8.2x - 13.0x |
10.7x |
| Forward P/E multiples |
12.2x - 17.8x |
14.8x |
| Fair Price |
0.03 - 3.94 |
1.77 |
| Upside |
-98.4% - 88.4% |
-15.4% |